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Background/aim: Although it has been shown that the neutrophil-to-lymphocyte ratio (NLR) may predict the progression of nonmuscle
invasive bladder cancer (NMIBC), its association with the recurrence of NMIBC has been poorly studied. The aim of this study is to
evaluate the association between NLR and disease recurrence in patients with NMIBC.
Materials and methods: The medical records of 428 consecutive initially diagnosed NMIBC patients who underwent transurethral
resection between January 2010 and July 2014 were retrospectively reviewed. Patients without a preoperative NLR (n = 6), without a
minimum of 6 months of follow-up (n = 56), who were lost to follow-up (n = 38), or who had progressive disease during follow-up (n =
42) were excluded. The demographics, tumor characteristics, and NLRs of patients with and without tumor recurrence were compared.
Results: Of 286 patients who met the inclusion criteria, 68 (17.43%) had recurrent disease. Tumor size (P = 0.198), tumor type (P =
0.929), and the presence of carcinoma in situ (P = 0.373) were also similar between groups. Patients with recurrent disease had a higher
mean NLR (2.62 ± 0.99 vs. 2.2 ± 0.96, P = 0.002).
Conclusion: Our results show that NLR may be used as a predictor of recurrence in patients with NMIBC; however, prospective studies
are required to validate these findings.
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1. Introduction
Urologists are faced with several specific challenges in
managing patients diagnosed with nonmuscle invasive
bladder cancer (NMIBC), a neoplasm that is characterized
by tumors that frequently recur and often progress to
potentially lethal muscle-invasive disease. Early diagnosis
and life-long surveillance are required to provide patients
with a reduced risk of tumor recurrence, as well as
potentially prevent disease progression. In spite of the
well-designed follow-up programs recommended by
current guidelines (1,2), recurrence is still seen in nearly
three-fourths of patients, and disease progression is seen in
a significant number (3). Even with a well-trained eye the
conventional follow-up of in-office cystoscopy and urine
cytology may still miss tumor recurrence in a significant
number of cases (4–7). Current advances in molecular
biomarkers that could potentially work synergistically with
conventional surveillance to improve overall sensitivity are
hopeful; however, their use is still not widely accepted due
to several limitations (8).
* Correspondence: emrah.yuruk@yahoo.com
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There is increasing evidence that supports the
involvement of systematic inflammation in cancer
development and progression (9). The neutrophil-tolymphocyte ratio (NLR) can be used as a marker of this
systematic inflammatory response (10). Poor outcomes
have been associated with an increased pretreatment
NLR in some cancers (11–14). Most recently evidence
has emerged supporting that the NLR can be correlated
with outcomes in bladder cancer managed with radical
cystectomy (15), as well as determining tumor invasiveness
(16). NLR may have a potential use for predicting outcomes
in bladder cancer patients; however, to our knowledge,
no study has investigated the prognostic significance of
NLR in the recurrence of NMIBC patients to date. Thus,
we evaluated the significance of NLR with regards to
recurrence of NMIBC.
2. Materials and methods
2.1. Study design
After approval by our institutional review board, the
medical records of 428 consecutive initially diagnosed
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NMIBC patients who underwent transurethral resection
(TURBT) between January 2010 and July 2014 were
retrospectively reviewed. Only the patients with primary
bladder tumors were included. Patients without a
preoperative NLR (n = 6), who did not have a minimum
of 6 months of follow-up (n = 56), who were lost to
follow-up (n = 38), or who were referred for cystectomy
or radiotherapy because of disease progression during the
follow-up (n = 42) were excluded. Of the patients with
progression to pT2 disease, 18 (42.9%) were diagnosed as
having a muscle-invasive disease in the second TURBT
and 24 (57.1%) during the follow-up period.
The NLR was calculated by using the neutrophil
and lymphocyte numbers measured in a pretreatment
complete blood count (CBC), a week before the operation.
If the patient required blood transfusion during the
preoperative period, NLR was calculated using the initial
CBC. The demographics, tumor characteristics, and NLRs
of patients with and without tumor recurrence were
compared.
2.2. TURBT procedure
After verification of a bladder tumor either by
ultrasonography or office cystoscopy, all patients were
initially treated with TURBT. The procedures were
performed under general anesthesia unless contraindicated
by anesthesiology. Before the operation, urine cultures of
all patients were checked and they were treated accordingly
in order to prevent septic complications. Resections were
performed using a Gyrus PlasmaKinetic Generator and
a 27-F resectoscope (Gyrus ACMI, Southborough, MA,
USA). After systematic cystoscopy, tumors up to 1 cm
in diameter were resected en bloc while larger tumors
were resected and referred to the pathologist separately
in fractions including the exophytic portion, underlying
bladder wall, and edges of the tumor. The pathological
specimens were evaluated by a single genitourinary
pathologist. Tumors were graded according to both WHO
1973 and 2004 grading systems (17,18) and staged to the
2009 TNM classification of urinary bladder cancer (19). A
single, immediate, postoperative intravesical instillation of
epirubicin was administered to all patients except for those
with overt/suspected bladder perforation or bleeding
that required bladder irrigation. A second TURBT was
performed after incomplete or insufficient initial TURBT
and in patients with T1 or grade 3 tumors.
2.3. Follow-up scheme
Risk scores for recurrence and progression of the disease
were calculated using EORTC risk tables and patients were
referred to intravesical chemotherapy or immunotherapy
whenever indicated (20). Patients were followed with
regular cystoscopy and urinary cytology at intervals
decided according to the risk scores of the individual
patients. Annual upper tract imaging using computerized

tomography–urography was performed in high-risk
patients. The first pathologically confirmed tumor relapse
in the bladder regardless of the tumor stage was accepted
as tumor recurrence.
2.4. Statistical analysis
Statistical analyses were performed using the Number
Cruncher Statistical System 2007 statistical software
package program (NCSS, LLC, Kaysville, UT, USA). In
addition to descriptive statistics (mean, standard deviation,
median, interquartile range), data were evaluated by
independent t-test for variables with normal distribution,
or by Fisher exact test and chi-square test for comparison
of qualitative data. To define the factors predictive of
recurrence, logistic regression analysis was performed.
Statistical significance was set at P < 0.05.
3. Results
Overall 286 patients with a mean age of 65.65 ± 11.4 years
(range: 18–95) and a mean follow-up period of 19.84 ±
17.66 months (range: 6–108) were included. The followup durations of patients with and without recurrence
were 32.3 ± 25.7 and 16.6 ± 12.2 months, respectively (P
< 0.001). Recurrence was seen in 68 (17.43%) patients.
Characteristics of the patients with and without tumor
recurrence are summarized in the Table.
The mean age, sex distribution, history of diabetes,
and rates of hypertension, coronary artery disease,
and hyperlipidemia were similar in patients with and
without recurrence (Table). Ta disease was reported in
77 (26.9%), T1 disease in 201 (70.3%), and carcinoma in
situ (CIS) in 8 (2.8%) patients. Of the entire cohort, 174
patients (60.8%) had low-grade and 112 (39.2%) patients
had high-grade disease. Neither T stage (P = 0.121) nor
grade (P = 0.205) was associated with recurrence during
the follow-up period. Overall 99 (34.6%) patients did
not receive postoperative immediate instillation due to
overt perforation (11 patients), suspected perforation (74
patients), or bleeding necessitating continued irrigation
(14 patients). Tumor size (P = 0.198), tumor appearance
(P = 0.929), and presence of CIS (P = 0.373) were also
similar between groups. A second TURBT was performed
in 217 (75.9%) patients. Having a second TURBT was not
associated with recurrence (P = 0.386). Recurrence rates
were similar among patients with (148 [51.7%] patients)
and without (138 [48.3%] patients) intravesical induction
and maintenance treatments (P = 0.620). However,
single tumors (P < 0.001) and postoperative epirubicin
installation (P < 0.001) were associated with reduced risk
of recurrence. Moreover, the mean NLR of patients with
recurrent disease (2.62 ± 0.99) was significantly higher
than that of nonrecurrent patients (2.2 ± 0.96) (P = 0.002,
odds ratio = 1.69, 95% confidence interval: 1.03–2.79).

235

YÜRÜK et al. / Turk J Med Sci
Table. Comparison of patient demographics, accompanying comorbidities, and tumor characteristics in patients with
and without recurrence (CIS: carcinoma in situ).
Characteristics

Recurrence
n = 68

No recurrence
n = 218

P*

Age

65.87 ± 10.94

62.22 ± 11.89

0.690

Male
Female

59 (86.76%)
9 (13.24%)

194 (88.99%)
24 (11.01%)

0.616

Diabetes mellitus

16 (23.53%)

38 (17.43%)

0.262

Coronary artery disease

13 (19.12%)

42 (19.27%)

0.978

Hypertension

32 (47.06%)

78 (35.78%)

0.095

Hyperlipidemia

2 (2.94%)

4 (1.83%)

0.578

Preoperative blood transfusion

1 (1.47%)

7 (3.21%)

0.447

Postoperative blood transfusion

2 (4.17%)

4 (2.30%)

0.480

9 (13.24%)
59 (86.76%)

44 (20.18%)
174 (79.82%)

0.198

32 (47.06%)
36 (52.94%)

155 (71.10%)
63 (29.90%)

0.0001

Papillary
Solid/flat

60 (88.24%)
8 (11.76%)

192 (88.89%)
24 (11.11%)

0.929

Presence of CIS

3 (4.41%)

5 (2.23%)

0.373

39 (13.63%)
29 (10.13%)

146 (51.04%)
70 (24.47%)

0.001

Sex

Size
<3 cm
≥3 cm
Number
Single
Multiple
Appearance

Postoperative immediate instillation
Epirubicin
None
*Fischer exact test and chi-square test.

Of note, blood transfusion was needed in 8 (2.79%)
patients in order to increase hemoglobin levels during the
preoperative period, whereas 6 (2.09%) patients required
transfusion during the postoperative period.
4. Discussion
An ideal biomarker to be used for monitoring recurrence
of NMIBC would be noninvasive, easily applicable, and
affordable, with both high sensitivity and specificity (21).
In theory this could potentially decrease the morbidity
associated with frequent cystoscopy, improve the patient’s
quality of life, and decrease costs by substituting a less
expensive noninvasive test for the more expensive

236

endoscopic procedure (22). For example, a highly specific
noninvasive adjunct to cystoscopy already used today is
voided urine cytology. This biomarker has good sensitivity
for detecting high-grade urothelial cancer; however,
sensitivity for the detection of low-grade tumors ranges
from only 4% to 31% (23). Cytology is also highly userdependent and dependent on the quality of the specimen
(24). A significant number of laboratory and clinical
investigations have developed numerous new urine
markers for the detection and diagnosis of bladder cancer
in an attempt to improve upon the shortcomings of urine
cytology. Indicators such as microsatellite polymorphism
analysis (25), ImmunoCyt (Diagnocure Inc, Quebec
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City, Canada) (26,27), the nuclear matrix protein-22
(Matritech, Newton, MA, USA) (28), fluorescence in situ
hybridization (FISH) analysis (Urovysion Systems Vysis,
Abbott Laboratories, Abbott Park IL, USA) (29), urinary
epidermal growth factor receptor, and epithelial cell
adhesion molecules have been studied (30). However, as
the sensitivity and specificity of these are low, they have
not become standard procedures for patients’ diagnosis
and follow-up surveillance (8,31). Thus, there is currently
no noninvasive standard method for screening for NMIBC
surveillance other than standard cystoscopy with urine
cytology. Other predictive factors of tumor recurrence such
as tumor number, diameter, prior recurrences, presence of
T1 disease, presence of CIS, and grade of the tumor have
been well established (32), and we hypothesized that NLR
could be used adjunctively as a prognostic biomarker to
predict the likelihood of recurrence of NMIBC.
The NLR is a nonspecific marker of systemic
inflammation that can easily be calculated by the ratio
of neutrophils to lymphocytes in a patient’s peripheral
blood sample. Obvious advantages of the NLR include
low cost, ease of application, and broad availability. This
biomarker could be useful in determining initial prognosis
when determining how often to screen patients. We
demonstrated that in a group of 286 patients with NMIBC,
patients with recurrent disease had a higher mean NLR.
The NLR has already been associated with different types
of cancer, as increased pretreatment NLR is associated
with poor prognosis in colorectal, gastric, renal cell, and
ovarian cancer (11–14), as well as malignant mesothelioma
and upper tract urothelial carcinoma (33,34). Gondo et al.
also recently demonstrated that a NLR threshold value
of <2.5 and ≥2.5 is an independent prognostic factor for
disease-specific survival risk in bladder cancer patients
treated with radical cystectomy (15). Another study by
Mano et al., which included 107 patients with NMIBC,
calculated that a NLR of >2.41 was associated with
disease progression and >2.43 was associated with disease
recurrence based on multivariate analysis (35). Similarly,
our study of a larger cohort found that not only could
the NLR have prognostic indications, but it could also
possibly be applied as an adjuvant tool to risk stratification
of patients on surveillance for NMIBC.
Although previous reports demonstrated the
association between tumor stage and grade (32), we could
not find such an association. This may be partly attributed
to the high second TURBT rates reported in the current
series. In a study by Sfakianos et al., it was reported that
a single TURBT was the only predictor of recurrence at 5
years (36).

The idea behind this is that inflammation may be
associated with different stages of tumor development
including initiation, promotion, malignant conversion,
invasion, and metastasis (37). Tachibana et al. previously
showed that bladder cancer cells produce granulocytecolony stimulating factor (G-CSF) and express G-CSF
receptors; thus, G-CSF production by bladder cancer
cells augments autocrine growth. This suggests that
the inflammatory response may play a crucial role in
malignant progression of bladder tumors (38). Neutrophils
in particular may also play a direct role in tumor
development as they are known to contain and secrete
vascular endothelial growth factor, a proangiogenic factor
(39). Cho et al. reported that patients with elevated NLR
exhibit relative lymphocytopenia and, as a result, may
mount a poor lymphocyte-mediated immune response
to malignancy, allowing for potential tumor progression
and in turn worsening their prognosis (13). In multivariate
analysis, pretreatment NLR is an independent prognostic
factor among these inflammatory parameters (15). It
would be reasonable to expect the NLR to correlate with
any amount of tumor recurrence, whether or not muscle
invasion is present, as the proposed inflammatory response
of neoplasia should be present.
This study has several limitations. It was performed in
a retrospective manner with a limited number of patients,
and our follow-up period was relatively short. In addition,
as only univariate analysis was performed, confounding
variables that were not accounted for could have skewed
our results. Both of these limitations may be responsible
for not demonstrating a statistically significant difference
in tumor size (P = 0.198), tumor appearance (P = 0.929),
and presence of CIS (P = 0.373) between patients with and
without recurrence. It is possible that patients with CIS
had a higher rate of disease progression and were thus not
included in the recurrence group. We also did not collect
data regarding corticosteroid use, immunosuppression,
other ongoing malignancies, or antibiotic therapies that
could affect a patient’s NLR. Although further study with a
larger sample size is necessary to validate the significance
of NLR in recurrence of NMIBC, we think that our results
represent a cost-effective adjuvant to current standards in
patients undergoing surveillance for recurrent NMIBC.
NLR may be used as a predictor of recurrence patients
with NMIBC; however, prospective studies are required
to validate these findings. Further research with regards
to both serum and urine biomarkers should have a goal
of being easily applied and cost-effective with both high
sensitivity and specificity.
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